Chinese Medical Journal最新文献

{"title":"Extracellular vesicles as a multicomponent biomarker platform for sepsis.","authors":"Feng Chen, Zhe Guo, Xuesong Wang, Haiyan Liao, Ziyi Wang, Zhiqing Chen, Zhong Wang","doi":"10.1097/CM9.0000000000003602","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003602","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 Chinese expert consensus on clinical utilization of laparoscopic and endoscopic cooperative surgery for gastric tumors.","authors":"Liang Shang, Ziyu Li, Pinghong Zhou, Zhenning Wang, Leping Li","doi":"10.1097/CM9.0000000000003639","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003639","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility-preserving treatment of endometrial cancer and endometrial atypical hyperplasia for patients with metabolic abnormalities: Challenge or opportunity?","authors":"Linlin Bo, Yiqin Wang, Yifan Feng, Jingyi Zhou, Yuanyuan Liu, Yijiao He, Yuanhe Zhai, Yuan Fan, Xiaobo Zhang, Rong Zhou, Danhua Shen, Li Tian, Jianliu Wang","doi":"10.1097/CM9.0000000000003721","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003721","url":null,"abstract":"<p><strong>Background: </strong>This study aims to evaluate the efficacy of a regimen that combines anti-estrogen therapy with treatments targeting glucose, lipid, and calcium metabolism in patients diagnosed with early-stage endometrial cancer (EC) and endometrial atypical hyperplasia (EAH).</p><p><strong>Methods: </strong>We conducted a retrospective analysis of patients with EC and EAH who were treated at Peking University People's Hospital between January 2018 and November 2023. The study examined the clinical profiles of the patients and assessed the efficacy of different treatment strategies.</p><p><strong>Results: </strong>A total of 285 patients were enrolled in the study, with 149 receiving anti-estrogen monotherapy and 136 receiving a combination therapy. The combination therapy group exhibited a higher incidence of elevated body mass index, insulin resistance, diabetes and hypertension (P <0.05). Pathology of EAH and metformin regimen were protective factors for shorter complete response time (P <0.05). Subsequent stratified analysis revealed that combination therapy with metformin significantly benefited patients with insulin resistance (hazard ratio [HR] = 1.888, 95% confidence interval [CI]: 1.313-2.713) and diabetes mellitus (HR = 2.749, 95% CI: 1.046-7.299).</p><p><strong>Conclusions: </strong>Fertility-sparing treatments for patients with metabolic risk factors may have poor efficacy. However, the integration of anti-estrogen therapy with the metabolic-targeting interventions, like metformin, appears to improve the outcomes of fertility-preserving strategies in this patient population.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of a novel directional deep brain stimulation system from China in the treatment of Parkinson's disease.","authors":"Hutao Xie, Xi Wu, Hualin Yu, Guihuai Wang, Zengguang Wang, Jie Zhang, Xiaodong Cai, Fangang Meng, Quan Zhang, Anchao Yang, Guanyu Zhu, Hua Zhang, Lin Shi, Yin Jiang, Dongmei Gao, Jinyu Xu, Jinghui Li, Xin Geng, Chang Qiu, Yuan Gao, Yangyang Xu, Yang Lu, Zhijuan Chen, Yuheng Liu, Doudou Zhang, Yuyang Shao, Wenbin Zhang, Wei Wang, Jianguo Zhang","doi":"10.1097/CM9.0000000000003696","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003696","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy.","authors":"Jia Hu, Tang Feng, Ling Zhang, Qinghua Zhou, Lingling Zhu","doi":"10.1097/CM9.0000000000003687","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003687","url":null,"abstract":"<p><strong>Abstract: </strong>Gut microbiota can modulate antitumor immunity and influence immune checkpoint blockade (ICB) therapy efficacy and treatment-associated toxicity. Variations in the therapeutic effect of ICB among individuals are partially attributed to microbiota. This review summarizes current knowledge on how specific bacterial species enhance or hinder ICB outcomes by regulating immune cell activation, antigen presentation, and systemic inflammation. The review further outlines translational strategies to optimize ICB, including microbiota-targeted interventions (e.g., prebiotics, fecal microbiota transplantation, and metabolite therapies) to overcome resistance and mitigate treatment-related toxicities, focusing on immune-related colitis. Additionally, emerging microbial biomarkers in melanoma, lung cancer, and hepatobiliary cancers that predict ICB response are discussed, highlighting the gut microbiome as a potential target for personalized cancer immunotherapy. By integrating mechanistic insights with clinical evidence, this review underscores the potential of microbiota-centered approaches to improve patient outcomes in ICB-based treatments, emphasizing the pivotal role of the gut microbiota in modulating both therapeutic efficacy and immune-related adverse events.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes of radical surgery after induction chemoimmunotherapy in clinical stage IIIA-IIIB (N2) non-small cell lung cancer.","authors":"Pengfei Li, Xin Wang, Miqi Gu, Kaili Huang, Long Tian, Jue Li, Qiang Wu, Ting Wang, Jintao He, Guowei Che, Qinghua Zhou","doi":"10.1097/CM9.0000000000003664","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003664","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy.","authors":"Yue Peng, Min Yu, Bozhao Li, Siyu Zhang, Jin Cheng, Feifan Wu, Shuailun Du, Jinbai Miao, Bin Hu, Igor A Olkhovsky, Suping Li","doi":"10.1097/CM9.0000000000003703","DOIUrl":"10.1097/CM9.0000000000003703","url":null,"abstract":"<p><strong>Abstract: </strong>Cancer represents a major worldwide disease burden marked by escalating incidence and mortality. While therapeutic advances persist, developing safer and precisely targeted modalities remains imperative. Nanomedicines emerges as a transformative paradigm leveraging distinctive physicochemical properties to achieve tumor-specific drug delivery, controlled release, and tumor microenvironment (TME) modulation. By synergizing passive enhanced permeation and retention effect-driven accumulation and active ligand-mediated targeting, nanoplatforms enhance pharmacokinetics, promote TME enrichment, and improve cellular internalization while mitigating systemic toxicity. Despite revolutionizing cancer therapy through enhanced treatment efficacy and reduced adverse effects, translational challenges persist in manufacturing scalability, longterm biosafety, and cost-efficiency. This review systematically analyzes cutting-edge nanoplatforms, including polymeric, lipidic, biomimetic, albumin-based, peptide engineered, DNA origami, and inorganic nanocarriers, while evaluating their strategic advantages and technical limitations across three therapeutic domains: immunotherapy, chemotherapy, and radiotherapy. By assessing structure-function correlations and clinical translation barriers, this work establishes mechanistic and translational references to advance oncological nanomedicine development.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of sonidegib in the treatment of locally advanced basal cell carcinoma: A multicenter retrospective experience in real-world China.","authors":"Jing Luan, Renliang He, Qinyuan Zhu, Xuezhu Xu, Yong Ai, Shujun Chen, Miaojian Wan, Wenyu Wu","doi":"10.1097/CM9.0000000000003444","DOIUrl":"10.1097/CM9.0000000000003444","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1508-1509"},"PeriodicalIF":7.5,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma succinate and the risks of cardiovascular events and recurrent stroke after ischemic stroke: A nested case-control study.","authors":"Leping Zhang, Hongyu Chen, Xiaoqing Bu, Zhong Ju, Tan Xu, Yonghong Zhang, Chongke Zhong","doi":"10.1097/CM9.0000000000003632","DOIUrl":"10.1097/CM9.0000000000003632","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1487-1489"},"PeriodicalIF":7.5,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term safety and effectiveness of roxadustat in Chinese patients with chronic kidney disease-associated anemia: The ROXSTAR registry.","authors":"Xiaoying Du, Yaomin Wang, Haifeng Yu, Jurong Yang, Weiming He, Zunsong Wang, Dongwen Zheng, Xiaowei Li, Shuijuan Shen, Dong Sun, Weimin Yu, Detian Li, Changyun Qian, Yiqing Wu, Shuting Pan, Jianghua Chen","doi":"10.1097/CM9.0000000000003672","DOIUrl":"10.1097/CM9.0000000000003672","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD)-associated anemia (CKD-anemia) is associated with poor survival, and hemoglobin targets are often not achieved with current therapies. Phase 3 trials have demonstrated the treatment efficacy of roxadustat for CKD-anemia. This phase 4 study aims to evaluate the long-term (52-week) safety and effectiveness of roxadustat in a broad real-world patient population with CKD-anemia with and without dialysis in China.</p><p><strong>Methods: </strong>This Phase 4 multicenter, open-label, prospective study, conducted from 24 November 2020 to 11 November 2022, evaluated the long-term safety and effectiveness of roxadustat for CKD-anemia in China. Patients aged ≥18 years with CKD-anemia with or without dialysis were included. The initial oral dose was 70-120 mg (weight-based followed by dose adjustment) over 52 weeks. The primary endpoint was safety based on adverse events (AEs). The secondary endpoints were hemoglobin changes from baseline and the proportion of patients who achieved mean hemoglobin ≥100 g/L. Effectiveness evaluable populations 1 (EE1) and EE2 included roxadustat-naïve and previously roxadustat-treated patients, respectively. The safety analysis set (SAF) included all patients who received ≥1 occasion.</p><p><strong>Results: </strong>The EE1, EE2, and SAF populations included 1804, 193, and 2021 patients, respectively. In the SAF, the mean age was 50 ± 14 years, and 1087 patients (53.8%) were male. Mean baseline hemoglobin was 96.9 ± 14.0 g/L in EE1 and 100.3 ± 12.9 g/L in EE2. In EE1, the mean (95% confidence interval) hemoglobin changes from baseline over weeks 24-36 and 36-52 were 14.2 (13.5-14.9) g/L and 14.3 (13.5-15.0) g/L, respectively. Over weeks 24-36 and 36-52, 83.3% and 86.1% of patients in EE1 and 82.7% and 84.7% in EE2 achieved mean hemoglobin ≥100 g/L, respectively. In the SAF, 1643 (81.3%) patients experienced treatment-emergent AEs (TEAEs). Overall, 219 (10.8%) patients experienced drug-related TEAEs. Thirty-eight (1.9%) patients died of TEAEs (unrelated to the study drug). Vascular access thrombosis was uncommon.</p><p><strong>Conclusions: </strong>Roxadustat (52 weeks) increased hemoglobin and maintained the treatment target in Chinese patients with CKD-anemia with acceptable safety, supporting its use in real-world settings.</p><p><strong>Registration: </strong>Chinese Clinical Trial Registry ( www.chictr.org.cn ) ChiCTR2100046322; CDE ( www.chinadrugtrials.org.cn ) CTR20201568.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1465-1476"},"PeriodicalIF":7.5,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}